Peter Thygesen

Dr. Peter Thygesen

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CSChristoffer Soendergaard
Christoffer Soendergaard
PKPeter Helding Kvist
Peter Helding Kvist
PTPeter Thygesen
Peter Thygesen
MRMats Reslow
Mats Reslow
Ole Haagen NielsenOle Haagen Nielsen
Ole Haagen Nielsen
THThomas Lindebo Holm
Thomas Lindebo Holm
Growth hormone (GH) resistance may develop as a consequence of inflammation during conditions such as inflammatory bowel disease, encompassing ulcerative colitis (UC). However, the specific role of the GH–insulin growth factor (IGF)-1-axis and/or the functional consequences of GH resistance in this condition are unclear. In situ hybridization targeting the GH receptor (GHR) and relevant transcriptional analyses were performed in patients with UC and in IL-10 knock-out mice with piroxicam accelerated colitis (PAC). Using cultured primary epithelial cells, the effects of inflammation on the molecular mechanisms governing GH resistance was verified. Also, the therapeutic potential of GH on mucosal healing was tested in the PAC model. Inflammation induced intestinal GH resistance in UC and experimental colitis by down-regulating GHR expression and up-regulating suppressor of cytokine signalling (SOCS) proteins. These effects are driven by pro-inflammatory mediators (tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6) as confirmed using primary epithelial cells. Treatment of experimental colitis with GH increased IGF-1 and body weight of the mice, but had no effects on colonic inflammation or mucosal healing. The high transcriptional similarity between UC and experimental colitis accentuates the formation of intestinal GH resistance during inflammation. Inflammation-induced GH resistance not only impairs general growth but induces a state of local resistance, which potentially impairs the actions of GH on mucosal healing during colitis when using long-acting GH therapy.

1 August 2017 in Growth Hormone & IGF Research
Verified
Journal Article
Closed access
PTPeter Thygesen
Peter Thygesen
HAHenrik Sune Andersen
Henrik Sune Andersen
CBCarsten Behrens
Carsten Behrens
JFJohannes Josef Fels
Johannes Josef Fels
LNLeif Nørskov-Lauritsen
Leif Nørskov-Lauritsen
NJNils Langeland Johansen
Nils Langeland Johansen

22 October 2009 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
PTPeter Thygesen
Peter Thygesen
PMPanos Macheras
Panos Macheras
APAchiel Van Peer
Achiel Van Peer

1 June 2007 in Peptides
Verified
Journal Article
Closed access
SKStine Kjellev
Stine Kjellev
EVElse Marie Vestergaard
Else Marie Vestergaard
Ebba NexoEbba Nexo
Ebba Nexo
PTPeter Thygesen
Peter Thygesen
MEMaria S. Eghøj
Maria S. Eghøj
SPSteen Seier Poulsen
Steen Seier Poulsen

1 January 2002 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
SLSøren T Larsen
Søren T Larsen
GNGunnar D Nielsen
Gunnar D Nielsen
PTPeter Thygesen
Peter Thygesen

1 February 1999 in Pharmacogenetics
Verified
Journal Article
Closed access
PTPeter Thygesen
Peter Thygesen
ARAngela Risch
Angela Risch
MSMichael Stacey
Michael Stacey
GFGiannoulis Fakis
Giannoulis Fakis
LTLindsay Takle
Lindsay Takle
ESedith sim
edith sim
Polymorphisms of N-acetyltransferase type 2 (NAT2) conferring the slow acetylator phenotype have been linked to increased susceptibility to arylamine-induced bladder cancer in Caucasians. Genes for NAT2, the other NAT isozyme, NAT1, and a NAT pseudogene (NATP) are found on 8p22, a region displaying loss of heterozygosity, particularly in invasive bladder tumours. A restriction enzyme digestion map has defined the relative positions of the NAT genes to each other and to adjacent CpG islands. NAT2, as a polymorphic gene of known function, is a potentially valuable marker for the detection of loss of heterozygosity in 8p22. Two approaches to investigate loss of heterozygosity at the NAT2 locus in bladder tumours have been used. (1) A cosmid containing NAT2 has been used in fluorescence in-situ hybridization on human exfoliated bladder cells collected from unselected bladder cancer outpatients. Loss of signal from the NAT2 cosmid was found in nine of the 20 patients. (2) A panel of 13 human bladder tumours was investigated for loss of heterozygosity using the polymorphism in the NAT2 gene as a marker. Loss of heterozygosity at the NAT2 locus has been compared with loss of heterozygosity at adjacent microsatellite marker sites known to be located on 8p. There is agreement between loss of heterozygosity at the NAT2 locus and adjacent microsatellite marker loci in 11 of the tumours but two of the tumours appear to show retention at the NAT2 locus. More extensive mapping of the region around the NAT loci, particularly on the centromeric side, is important to pinpoint possible tumour suppressor genes or their modifiers in the region. There are no other expressed sequences known in this region and therefore NAT genes are important genetic landmarks.